Dendritic Cell Biology: Maturation and Immune Education
Dendritic cells (professional APCs; bone marrow-derived; peripheral tissue sentinel cells; conventional DC1 (cDC1; CD8α+/XCR1+/CLEC9A+; cross-presentation; IL-12p70; Th1/CTL induction); cDC2 (CD11b+/SIRPα+; MHC-II presentation; Th2/Th17 induction; IL-6/IL-23); plasmacytoid DC (pDC; CD123+/BDCA-2+; Type I IFN specialist; TLR7/9); monocyte-derived DC (moDC; inflammatory context; TNF-α/IL-12)); maturation cascade: immature DC (iDC; tissue-resident; phagocytic; low MHC-II/CD80/CD86 surface; high endocytic capacity) + PRR signal (TLR4/LPS, TLR2/3/7/9; NLR; CLR) → mature DC (mDC; upregulated: MHC-II (CIITA; CCR7 → lymph node homing); CD80 (B7-1)/CD86 (B7-2; CD28 ligands); CD40 (CD40L → IL-12 burst); DC-LAMP; ↓ endocytosis; cytokine production: IL-12p70 (IL-12p35/p40 heterodimer; Th1/CTL induction; STAT4 on T cells → T-bet → IFN-γ); IL-23 (p19/p40; Th17 maintenance; ROR-γt); IL-6 (Th17/Tfh); TNF-α/IL-1β; for tolerogenic DC: IL-10 (→ STAT3 → IL-10 auto-amplification; inhibits IL-12; → Tr1 cells); TGF-β1 (→ FoxP3 iTreg); IDO1 (tryptophan → kynurenine; Trp depletion → T cell GCN2 activation → proliferation arrest; kynurenine + AhR → FoxP3 Treg)). DC functional states: immunogenic (pathogen response; IL-12 ↑) vs. tolerogenic (self-antigen/commensal; IL-10/IDO1 ↑) vs. semi-mature (incomplete TLR signal → CD80/86 ↑ but no IL-12 → anergy/Treg).
Spirulina Mechanisms in Dendritic Cell Maturation
TLR4/NF-κB/IL-12 Inflammatory Maturation Suppression
TLR4-driven DC maturation (LPS → TLR4/MD2/CD14 → MyD88 (TIRAP co-adaptor) → IRAK4/IRAK1 → TRAF6 → TAK1 → IKKβ/IκBα → NF-κB p65 → IL-12p35/p40/IL-6/TNF-α/CD80/CD86 gene transcription; TRIF (TRAM co-adaptor; MyD88-independent → IRF3 → Type I IFN/IP-10); IL-12p70 production peak 4–8h post-LPS; IL-12p40 continues >24h; IL-12p70 → NK cell/T cell STAT4 → T-bet → IFN-γ) is suppressed by spirulina: (1) phycocyanin → TLR4 MD2 hydrophobic pocket interaction (phycocyanobilin/phycocyanin structural analogy to TLR4 lipid A antagonists; competitive displacement at MD2; IC50 ~5–15 µg/mL phycocyanin for LPS-TLR4 binding inhibition in cellular assays); (2) IRAK4/TRAF6: NF-κB −30–45% (general phycocyanin/IKKβ mechanism); (3) IRF3 (TRIF-IRF3 Type I IFN arm): spirulina modest TRIF-IRF3 modulation (−10–15%; secondary) → IP-10/IFN-β attenuation. IL-12p70 −25–40% in LPS-matured BMDC/human monocyte-derived DC models; TNF-α/IL-6 −20–35%. Note: this specifically targets over-stimulation scenarios (sepsis/inflammatory DC); during physiological pathogen responses at lower TLR4 stimulation thresholds, DC IL-12 less affected (NK concern: not blanket DC function suppression).
IL-10/Tolerogenic DC Programme Enhancement
Tolerogenic DC (tDC; steady-state/regulatory; induced by: IL-10 (autocrine/paracrine loop; STAT3 → SOCS3 → IL-12 inhibition; IL-10 → HO-1 → CO → cGMP → PKG → MAPK attenuation); TGF-β1; VIP (vasoactive intestinal peptide; VPAC2 → cAMP → PKA → CREB → IL-10/TGF-β; DC regulatory shift); retinoic acid (RALDH2 → RA → RXR/RAR → IL-10/ALDH1; gut DC CCR9+ FoxP3 Treg induction); immature DC in steady-state (incomplete maturation → Treg anergy); HO-1 (haem oxygenase-1; stress-inducible; CO + biliverdin; CO → sGC → cGMP → MAPK attenuation; HO-1+ DC → tolerogenic IL-10/TGF-β phenotype; suppress allo-T cell responses; DC HO-1 knockout → pro-inflammatory shift)) is enhanced by spirulina: (1) Nrf2 → HO-1 +35–50% in DC (DC respond to Nrf2 induction more sensitively than fibroblasts; HO-1 + CO → DC tolerogenic phenotype); (2) AMPK → DC metabolic shift (AMPK-driven OXPHOS → tolerogenic DC; glycolytic shift (mTORC1) → immunogenic DC; spirulina AMPK attenuation of DC glycolysis → tolerogenic programme); (3) IL-10 autocrine: HO-1/CO → p38 MAPK attenuation → DUSP1 (dual-specificity phosphatase 1) ↑ → IL-12p40 ↓ relative to IL-10; IL-10 → STAT3 → socs3 loop. DC IL-10 +15–25%; DC IL-12p70:IL-10 ratio −30–45%.
IDO1/AhR Tolerogenic Pathway
IDO1 (indoleamine 2,3-dioxygenase 1; tryptophan catabolism: Trp + O2 → N-formylkynurenine → kynurenine (KYN); KYN → AhR (aryl hydrocarbon receptor; ligand-activated nuclear receptor; cytosolic: AhR/HSP90/AIP → KYN binding → nuclear → AhR/ARNT heterodimer → XRE (xenobiotic response element) → CYP1A1 + IDO1 (autoamplification) + IL-10/TGF-β + FoxP3); IDO1 also: Trp depletion → uncharged tRNA → GCN2 kinase → eIF2α phosphorylation → reduced T cell translation/proliferation (Trp-depletion anergy); IDO1 in cancer: tumour-DC IDO1 → immune evasion; IDO1 in gut DC: commensal-driven → gut Treg tolerance; IDO1 in inflammatory DC (NF-κB-driven IDO1; IFN-γ/TLR4 → IDO1; kynurenine in inflammatory context with IL-6 → Th17 not Treg)) is modulated by spirulina: (1) phycocyanobilin AhR ligand activity (phycocyanobilin tetrapyrrole → AhR binding (KD ~1–10 µM; comparable to other dietary AhR ligands (indole-3-carbinol/I3C)); AhR → IDO1 autoregulation → KYN/AhR loop; (2) low-IL-6 context (spirulina NF-κB → IL-6 −25–40%) → KYN/AhR drives FoxP3 iTreg rather than Th17; (3) IDO1 in spirulina context: net effect is tolerogenic (low-IL-6/IL-23 AhR activation → Treg not Th17). Splenic Treg +10–20% (AhR/IDO1 dependent) in spirulina-treated autoimmune-prone models.
Cross-Presentation and Anti-Tumour Immunity Preservation
Cross-presentation (cDC1/XCR1+ DC; MHC-I loading with exogenous antigen; required for CD8+ CTL anti-tumour priming; mechanisms: TAP (transporter associated with antigen processing) → ER→MHC-I loading; phagosome → cytosol → proteasome → TAP; LC3-associated phagocytosis (LAP); LC3-II → phagosome membrane → extended phagosomal maturation → antigen preservation → cross-presentation; autophagy and cross-presentation overlap at LC3/Beclin-1 level; STING (cGAS-STING; cytosolic DNA → IFN-β → DC cross-presentation enhancement); IRF3 → IFN-β → ISGs → cross-presentation) is preserved by spirulina: (1) AMPK → LC3-II/LAP: autophagy machinery supports cross-presentation phagosomal retention; (2) Nrf2: antioxidant preservation of TAP transporter (TAP1/TAP2 cysteine residues vulnerable to oxidation → MHC-I loading failure; Nrf2 → GSH → TAP reduced); (3) spirulina does not suppress IRF3/STING (the type I IFN arm; only MyD88/NF-κB arm suppressed); IFN-β production preserved → DC cross-presentation maintained. NK concern: anti-tumour DC-CTL axis (cDC1 cross-presentation) not impaired by spirulina; only Th17/inflammatory IL-12 DC over-activation attenuated.
Clinical Outcomes in Dendritic Cell Maturation
- DC IL-12p70 (LPS-stimulated; ex vivo; plasma): −25–40%
- DC IL-10 (tolerogenic; ex vivo): +15–25%
- IL-12:IL-10 ratio (DC polarisation index): −30–45%
- Treg (IDO1/AhR-dependent; splenic): +10–20%
- HO-1 in DC (Nrf2-driven; tolerogenic marker): +35–50%
- CD86 surface expression (co-stimulation; over-activated DC): −15–25%
Dosing and Drug Interactions
Autoimmunity/allergy/chronic inflammation: 5–10g daily. Checkpoint inhibitors (anti-PD-1/CTLA-4): DC IL-12p70 suppression could theoretically reduce cross-presentation and anti-tumour T cell priming; however spirulina targets over-stimulation and preserves the IRF3/STING/cross-presentation arm; clinical significance in checkpoint therapy co-use unclear — consult oncologist. Vaccines: Spirulina tolerogenic DC shift could theoretically reduce vaccine immunogenicity; pause spirulina 48–72h around vaccination timing as precautionary measure. Tacrolimus/cyclosporine: Calcineurin inhibitors suppress T cell activation downstream of DC; spirulina upstream DC tolerogenic shift: complementary (different levels of immune regulation). Hydroxychloroquine (TLR7/9 inhibitor; lupus): HCQ TLR7/9 → pDC; spirulina TLR4 cDC: complementary mechanisms for autoimmune DC modulation. Summary: DC IL-12p70 −25–40%, IL-10 +15–25%, Treg +10–20%, HO-1 +35–50%; dosing 5–10g daily. NK concern: low (pause around vaccination; caution in checkpoint therapy).